Please login to the form below

Not currently logged in
Email:
Password:

quarterly sales

This page shows the latest quarterly sales news and features for those working in and with pharma, biotech and healthcare.

AZ agrees to $320m deal for Zoladex

AZ agrees to $320m deal for Zoladex

products. The deal, which is expected to close by the end of March, will see AZ receive a $250m upfront payment for the rights, with double-digit quarterly sales-based payments ... ongoing. A further $70m is also up for grabs should Zoladex (goserelin

Latest news

  • GSK's Witty ends on a high, but warns 2017 looking 'uncertain' GSK's Witty ends on a high, but warns 2017 looking 'uncertain'

    Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline. ... Other generics from Mylan and Hikma are under regulatory review, however, which could be directly substitutable and accelerate the decline in the brand's

  • 2017 set to be a 2017 set to be a "defining year" for AZ

    The last AZ drug to fall over the 'patent cliff' - cholesterol-lowerer Crestor (rosuvastatin) - saw sales cut in half in the fourth quarter after the loss of US patent protection, with ... The decline was, however, offset by good growth for non-small

  • Tecentriq growth offsets Avastin's US decline at Roche Tecentriq growth offsets Avastin's US decline at Roche

    Roche is hoping that while Avastin is likely to see some cannibalisation of sales from Tecentriq, combination use could support its older drug. ... Overall, Roche reported a 3% increase in pharma sales to CHF 39bn, and the company is expecting low- to mid

  • AbbVie weak on new drug sales, but Humira stays strong AbbVie weak on new drug sales, but Humira stays strong

    AbbVie weak on new drug sales, but Humira stays strong. World’ s biggest-selling drug has record quarter while Imbruvica and Venclexta fall short. ... Imbruvica - which is also sold by Johnson &Johnson - should hit $2.4bn in sales this year, of which

  • J&J pondering future of diabetes device assets J&J pondering future of diabetes device assets

    J&J pondering future of diabetes device assets. Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales. ... The diabetes care announcement came as J&J's fourth quarter sales fell below analyst estimates, with top-selling drug

More from news
Approximately 9 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics